Rudolf de Boer, RA de Boer
Rudolf de Boer, RA de Boer
Professor in Cardiology, Erasmus MC, Rotterdam, the Netherlands
Verified email at - Homepage
Cited by
Cited by
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart …
TA McDonagh, M Metra, M Adamo, RS Gardner, A Baumbach, M Böhm, ...
European heart journal 42 (36), 3599-3726, 2021
Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ...
New England Journal of Medicine 381 (21), 1995-2008, 2019
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the …
B Pieske, C Tschöpe, RA De Boer, AG Fraser, SD Anker, E Donal, ...
European heart journal 40 (40), 3297-3317, 2019
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ...
New England Journal of Medicine 387 (12), 1089-1098, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology …
AR Lyon, T López-Fernández, LS Couch, R Asteggiano, MC Aznar, ...
European Heart Journal-Cardiovascular Imaging 23 (10), e333-e465, 2022
Identification of seven loci affecting mean telomere length and their association with disease
V Codd, CP Nelson, E Albrecht, M Mangino, J Deelen, JL Buxton, ...
Nature genetics 45 (4), 422-427, 2013
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
RA de Boer, DJA Lok, T Jaarsma, P van der Meer, AA Voors, HL Hillege, ...
Annals of medicine 43 (1), 60-68, 2011
Galectin‐3: a novel mediator of heart failure development and progression
RA de Boer, AA Voors, P Muntendam, WH van Gilst, DJ van Veldhuisen
European journal of heart failure 11 (9), 811-817, 2009
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association …
PM Seferovic, P Ponikowski, SD Anker, J Bauersachs, O Chioncel, ...
European journal of heart failure 21 (10), 1169-1186, 2019
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND
FP Brouwers, RA de Boer, P van der Harst, AA Voors, RT Gansevoort, ...
European heart journal 34 (19), 1424-1431, 2013
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
PM Seferović, MC Petrie, GS Filippatos, SD Anker, G Rosano, ...
European journal of heart failure 20 (5), 853-872, 2018
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations
C Mueller, K McDonald, RA de Boer, A Maisel, JGF Cleland, ...
European journal of heart failure 21 (6), 715-731, 2019
The ATLAS experiment at the CERN large hadron collider
A Collaboration, G Aad, E Abat, J Abdallah, AA Abdelalim, A Abdesselam, ...
Jinst 3, S08003, 2008
Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association
SL Chow, AS Maisel, I Anand, B Bozkurt, RA De Boer, GM Felker, ...
Circulation 135 (22), e1054-e1091, 2017
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis
L Yu, WPT Ruifrok, M Meissner, EM Bos, H Van Goor, B Sanjabi, ...
Circulation: Heart Failure 6 (1), 107-117, 2013
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C …
AR Lyon, S Dent, S Stanway, H Earl, C Brezden‐Masley, A Cohen‐Solal, ...
European journal of heart failure 22 (11), 1945-1960, 2020
The fibrosis marker galectin‐3 and outcome in the general population
RA De Boer, DJ Van Veldhuisen, RT Gansevoort, AC Muller Kobold, ...
Journal of internal medicine 272 (1), 55-64, 2012
New gene functions in megakaryopoiesis and platelet formation
C Gieger, A Radhakrishnan, A Cvejic, W Tang, E Porcu, G Pistis, ...
Nature 480 (7376), 201-208, 2011
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...
Jama 323 (14), 1353-1368, 2020
The system can't perform the operation now. Try again later.
Articles 1–20